Cardiovascular Effects of GLP-1 Receptor Activation

NCT03101930 · Completed

Last updated 2026-05-28

This trial tests how a GLP-1 receptor activator affects blood vessel function in adults with obesity and prediabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind basic-science study

Participants 329 people

Who can join Ages 18–65 · all sexes

Timeline Started 2017-05 · est. completion 2021-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03101930 ↗

Description as written by the study sponsor.

This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual factors that modulate GLP1R sensitivity can modify the effect of these analogues on cardiovascular risk.

Treatments tested

Liraglutide Drug

subcutaneous liraglutide daily
Sitagliptin Drug

oral sitagliptin daily
hypocaloric diet Other

Reduced calorie intake to achieve weight loss.
Placebos Drug

Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
Exendin (9-39) Drug

All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.

Main thing measured	Change in Flow-mediated Dilation
Sponsor	Vanderbilt University Medical Center
Conditions studied	Obesity, PreDiabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03101930 ↗